Introduction
The effectiveness of non-myeloablative allogeneic hematopoietic SCT has been reported in advanced hematologic malignancies using matched and mismatched donors. [1] [2] [3] [4] However, significant limitations continue because of relapse, GVHD, infections and treatment-related mortality. [5] [6] [7] Host and graft T-cell depletion during the conditioning regimen often results in lower rejection and GVHD rates; however, most methods used curtail the graft-versus-tumor effect and may allow an increase in infections. [8] [9] [10] [11] [12] Alemtuzumab, a humanized monoclonal IgG antibody against CD52, has been suggested as a means to effectively T-cell deplete a graft while maintaining natural killer (NK) cells, felt to be crucial to the anticancer effect of allogeneic transplantation. 13, 14 In the ablative setting, use of alemtuzumab for T-cell depletion combined with a donor lymphocyte boost after recovery has been associated with an improved toxicity profile without an increase in relapse compared to historical controls with matched donors, making its use attractive in the non-myeloablative setting. [15] [16] [17] [18] For improvements in immune recovery and response duration, there is mounting evidence supporting the efficacy of donor lymphocyte infusions (DLIs) in patients with hematopoietic malignancies. [19] [20] [21] [22] However, there are limited data concerning the timing and dose of lymphocyte infusions that can be safely given shortly after T-cell depleted non-myeloablative therapy. We present a case series of 69 consecutive patients who underwent T-cell depleted non-myeloablative therapy using a 3-6/6 HLAmatched related donor graft and subsequently received DLIs shortly after transplantation. Response, development of acute GVHD (aGVHD) and survival are reported.
Patients and methods

Patients
Patients in this cohort study are a subset of our center's larger prospective, non-myeloablative trial. They were included if they had a hematologic malignancy or marrow failure syndrome and had consented and were treated on IRB-approved protocols for T-cell depleted non-myeloablative allogeneic hematopoietic SCT and long-term follow-up studies as described elsewhere. 4, 18 Preparative regimen Briefly, the preparative regimen included 5 days of i.v. alemtuzumab 20 mg/day on days À4 to 0 and 4 days of fludarabine 30 mg/m 2 and CY 500 mg/m 2 per day on days À5 to À2. Recipients of matched sibling stem cells did not receive any other therapy for post transplant prophylaxis of aGVHD, whereas patients who received a family member 3-5/6 HLA-matched graft received mycophenolate 1 g orally twice daily for 60 days after transplantation. Starting day þ 1, patients received filgrastim 5 mcg/kg (rounded to nearest vial) till absolute neutrophil count was 41 Â 10 9 /l for 2 days. None of the patients was able to undergo ablative therapy because of advanced age, history of aspergillus or other fungal infection, no available matched donor and/or other co-morbidities. Chimerism was defined using short tandem repeat analysis as described by us. 4 Donor lymphocyte infusions Donor lymphocyte infusions were planned for all patients within the first few months of transplantation if they had at least 2.5% donor chimerism and did not have severe GVHD, but had relapse or persistence of disease (by conventional or molecular testing), high risk of relapse (patients in second or greater remission), or decreasing (at least a 15% decrease) or very low donor chimerism (under 20%). Deviations from this timing were primarily due to restaging evaluations, assuring patients had co-morbidities stabilized, delays in chimerism assessments, donor availability and insurance reviews. Lymphocytes were collected without growth factor mobilization and were a mixture of fresh or frozen products. Although we planned at least one boost for all patients following this T-cell depleted transplant procedure, the optimal dosage of lymphocytes in this setting is unknown and thus was chosen at the physician's discretion considering the patient's disease and clinical status. Thus, this report is a retrospective review of the historical cohort of patients on the study who actually received at least one DLI. DLI dosages thus ranged from 1 Â 10 4 CD3 þ cells/kg to 3.27 Â 10 8 CD3 þ cells/kg. Patients were considered for a second and third DLI 8 weeks apart if they did not have 4grade 2 toxicity from the initial DLI or donor availability, and insurance approved the infusion. In those who had more than one infusion, patients did not have doses escalated from the original dose unless there was persistence or relapse of disease at the time of the next planned DLI.
Toxicity and response
For evaluation of toxicity and response, patients were grouped into four categories within the range of cell doses delivered (Table 1 ) and were considered evaluable from the day of first DLI. Acute GVHD was graded according to consensus criteria and CTC v3 was used for all other toxicities. Recognizing that aGVHD pathology in the nonablative and DLI setting may occur late, we tabulated skin, gut and liver toxicity consistent with aGVHD at any time in the year after infusion as aGVHD. Toxicities were formally recorded for all patients twice weekly for the first 100 days, at each follow-up visit, and as needed intercurrently. DLI response was assessed by examining the underlying disease status 4-6 weeks after infusion and thereafter at 3-month intervals for the first year and then as clinically indicated, using recently updated standardized disease response criterion.
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Results
Patient characteristics
Lymphocyte boosts of some type were planned for all patients in this feasibility study for T-cell depleted nonmyeloablative therapy treated between December 1999 and September 2006, though the doses were not proscribed prospectively, as little data were available during the conduct of the study on optimal dosing strategies. Of seventy-five 5-6/6 HLA-matched sibling transplanted patients, there were 52 (70%) who received at least one DLI. Twenty-three of the 75 subjects who did not receive a DLI had at least grade 2 GVHD (18), secondary graft failure (2) or early treatment-related mortality (3).
In the other cohort of patients on the feasibility studies of 3-5/6 HLA-matched family member non-myeloablative transplantation, 17 of the 24 treated patients received at least 1 DLI (71%). Of the seven who did not receive a DLI, two had early treatment-related death, two graft rejection and three severe GVHD.
Thus, this is a report of 69 of the 99 total patients transplanted with a median age of 57 years in the matched and 46 in the mismatched group (range 18-70 years). Forty-one (59%) patients had leukemia or myelodysplasia (MDS), 17 (25%) had lymphoma or myeloma, and 11 (16%) had myeloproliferative disorders or hemoglobinopathy. At the time of DLI, 48 patients had persistent disease, whereas 2 were given DLI for a decreasing donor percentage not related to relapse, and 19 had high-risk disease including multiple relapses (XCR2), refractory disease or induction failure before transplantation ( Table 2) . The interval between transplant and DLI administration ranged from 10 to 630 days with a median of 50 days. Four patients had their first DLI within 4 weeks (all had very low donor chimerism and three of four patients had persistent marrow disease as well), whereas 10 patients had their first beginning X4 months from transplant. Twenty-two patients received at least two DLIs, 18 in the matched group and 4 in the mismatched group.
Toxicity of early delivery of DLI Neutropenia was encountered in 12 patients (23%) in the matched group and in 3 (18%) in the mismatched group. Nine reactivated CMV and CMV disease occurred in two of these patients (both were neutropenic). A total of 21 of the 52 patients in the matched and 5 of the 17 patients in the mismatched group experienced some degree of aGVHD (Table 3 ). In the non-myeloablative and DLI setting, the occurrence of pathologic and clinical changes consistent with aGVHD are noted to occur beyond day 100 and therefore we agree with earlier suggestions to code these occurrences as aGVHD 26 beyond this time frame (we have seen this up to 12 months after infusion) to more accurately reflect the clinical syndrome rather than provide a potentially false sense of lower risk for this severe complication. Skin was the most commonly involved organ and was involved in 20 patients, whereas 15 patients had GI disease and 8 had liver disease. However, only 9 of 52 patients (17%) in the matched group and 3 of 17 patients (18%) in the mismatched group had severe (grades 3-4) aGVHD. Seven of the 18 patients in the matched group who had more than 1 DLI developed aGVHD and 3 of these were severe. One of the four in the mismatched group who had more than 1 DLI developed severe aGVHD. Five patients died from the direct effect of aGVHD (Table 4) . None of the patients in the matched or mismatched group who did not have aGVHD with the first DLI experienced severe aGVHD with subsequent infusions at the same dose level. In the matched setting, 4 of 14 patients (29%) receiving a median dose of 1 Â 10 7 CD3 þ cells/kg developed severe aGVHD, whereas only 4 of 31 patients (13%) receiving a median dose of 1 Â 10 6 CD3 þ cells/kg developed severe aGVHD. In the mismatched setting, two of nine patients (22%) receiving a median dose of 1 Â 10 6 CD3 þ cells/kg developed severe aGVHD (one patient both of gut and liver) and only one of seven patients (14%) receiving a median dose of 1 Â 10 5 CD3 þ cells/kg did so. Only one of the long-term surviving patients is noted to have significant chronic GVHD.
Response and survival
At the time of DLI, 48 patients had relapse or persistent disease as the main determinant leading to DLI, whereas 2 patients were given DLI for decreasing donor percentage (owing to nonrelapse rejection or viral disease). The remaining 19 patients had high-risk disease including multiple relapses (XCR2) or previous induction failure. Following administration of DLI, 14 patients had a decrease in donor hematopoiesis after DLI. Eleven were coincident with progressive disease and three with CMV disease and/or antiviral therapy. Importantly, 7 of 22 leukemia patients (32%), 7 of 16 lymphoma patients (44%) and 4 of 10 patients with myeloproliferative disorders/ hemoglobinopathy with measurable disease before DLI (40%) attained a CR after infusion (Table 5) .
Relapse was by far the most common cause of death, accounting for 37 of the 60 deaths, whereas five patients died primarily from GVHD and 10 primarily from infections. With median follow-ups of survivors of 57 months from transplant (range 34-72 months) and 55 months from first DLI (range 32-71 months), overall median post-DLI survival at time of publication is 6 months for those who attain remission, with 9 of 69 patients still alive and disease-free. Long-term outcomes for each disease type are similar. Although our survival curves indicate that those who attained a complete response had a better survival than non-responders in the first few years, the long follow-up of this cohort of patients indicates that all the groups had significant death rates indicating great room for improvement (Figures 1a and b) .
Discussion
There is significant evidence that allogeneic immunotherapy may improve survival not based solely on rescuing patients from very high doses of chemotherapy, but through the new immune system attacking the cancer cells. Evidence for this includes a temporal relationship between GVHD and hematologic remission; 21, 27 reduced incidence of leukemic relapse after allogeneic transplantation compared to syngeneic transplantation; 28 and a reduced incidence of leukemic relapse in allogeneic transplant recipients who do develop GVHD compared to those who do not. 29 The promise of non-myeloablative therapy lies in exploiting this antitumor effect in a safe way.
Non-myeloablative hematopoietic transplantation is an effective approach to manage advanced hematologic malignancies, allowing the treatment of older, more infirm patients. However, failure rates that are due primarily to procedure toxicity, relapse or infections are a concern. 1, 4, 5, 6, 18, 30 Although stringent T-cell depletion has been used to improve the safety of allogeneic therapy, there are concerns of heightened infections and tumor relapse through interference with the antitumor effect discussed above. 8, 9, 10, 31 The addition of alemtuzumab, a monoclonal antibody targeting B and T cells that express CD52, has been shown to minimize aGVHD while allowing reliable engraftment and maintenance of encouraging antitumor responses, possibly because of its less complete depletion of the T-cell pool and relative sparing of the NK cell population. NK cells from a donor may attack cancers in a new host by recognizing the lack of antigens on the cancer cells because of HLA disparities between host and donor. Recent work by the Perugia group has provided further clinical support for the importance of this cell population by noting that patients with an NK alloreactive donor have a better outcome from transplantation compared to those with a matched non-alloreactive donor. 32 However, immune recovery still leaves much to be desired as relapse rates and infection rates remain high with this and other approaches to non-myeloablative therapy. Therefore, post transplantation immunotherapy in the form of bulk dose or selected lymphocyte subset infusions remains a focus of current efforts. 4, [15] [16] [17] [18] 33 Recent reports using DLI for hematopoietic malignancies have noted efficacy for this population. The EBMT Acute Leukemia Working Party has recently reported use primarily for relapse after ablative therapy. In this population, the median time of relapse after initial transplant (and subsequent DLI with or without reinduction chemotherapy) was 5 months with a median of 10 7 CD3/kg in the matched donor setting used. Thirty-five percent attained a remission, though forty-three percent experienced aGVHD. 22 Earlier reports on DLI after alemtuzumab reduced-intensity regimens have focused primarily on matched donors and lymphomatous disorders with infusions long removed from the time of transplantation. Peggs et al. 34 have noted that a dose of 10 6 CD3 þ cells/kg was well tolerated in that setting but that it did not result in a significant rate of durable responses in their patients. They also noted that matched unrelated donor recipients experienced a high rate of severe aGVHD even when the DLI at this dose was delivered many months after transplantation. However, little is known about the tolerable doses, safety or efficacy of lymphocyte infusions shortly after T-cell depleted non-myeloablative therapy, particularly in mismatched recipients.
We report on 69 consecutive patients (3-6/6 HLA matched) who received a DLI shortly after non-myeloablative allogeneic transplantation using alemtuzumab, fludarabine and CY. Although levels of alemtuzumab remain measurable in the body for weeks after delivery of these doses, the concentration is likely at sublytic levels within a few weeks of transplant. 35 Most patients had their first infusion within 3 months of transplantation and the majority had high risk or active disease. Our cohort is biased though in that although having a DLI was standardized within this cohort, the timing and dosage were varied according to the clinical status of the patient, disease status and physician's discretion and not in an objective pre-planned method. With this caveat, we agree with earlier reports involving matched sibling transplantation and conclude that DLI doses in the range of 1 Â 10 6 CD3 þ cells/kg in the HLA-matched sibling setting appear to be safe when delivered soon after T-cell depleted nonmyeloablative transplantation with only 3 of 31 patients (10%) experiencing severe aGVHD with the first or any subsequent DLI at this dose. Early infusion in the second month as in our study is tolerated similarly to the late infusions reported earlier by Peggs and colleagues.
Recent interesting work has reported manipulating post transplant T-cell infusions to minimize their toxicity in the haploidentical setting by depleting certain subsets or 'alloreactive' cells. 36 To our knowledge, the current report is the first to include haploidentical donors receiving unmanipulated DLIs shortly after T-cell depleted nonmyeloablative transplantation in this manner. In this group, DLI soon after transplant in the range of 1 Â 10 5 CD3 þ cells/kg appears to be safe with only one of seven patients (14%) experiencing severe aGVHD with the first or any subsequent DLI at this dose. Although there were responses at higher doses of DLI as well, over 20% of patients in each of the matched and mismatched groups had severe GVHD at the next higher dose range than that recommended above, making correlation of higher doses to better overall response non-feasible in this report.
As a review of our experience with this historical cohort, our report is limited in that although a DLI was planned for all transplanted patients on study, the doses and numbers of DLI given were not predetermined but were related to patient's clinical status, physician discretion, dose available from a donor or insurance approval. This formal statistical comparison between dose levels would not be appropriate. The trends reported herein, however, are still instructive in that the responses were noted and, when combined with the toxicities encountered, it provides a framework for planned comparative studies.
Response to DLI as reported in the literature varies, particularly with myeloid diseases that often progress quickly. We document response to unmanipulated DLI for patients with high-risk lymphoid or myeloid diseases. Eighteen of 48 patients (38%) infused in the presence of measurable disease attained a complete remission. However, with only 13% remaining as long-term disease-free survivors, relapse remains the primary problem, followed by infectious-related deaths. The exact contribution of DLIs to these outcomes remains unclear as most infusions were provided early in recovery, when the full effect of the initial infusion may not yet be evident. However, given the reports of higher relapse and infections in the T-cell depleted setting without post transplant DLI, a post transplant T-cell boost of some sort is considered important to optimize outcomes, although the most advantageous way to do this is unclear. Our data indicate that DLI after both matched and mismatched T-cell depleted non-myeloablative therapy can be well tolerated and even provided early after transplantation and serves as a basis to compare safety and efficacy of future studies. Efforts to improve post transplant immune therapies to provide more durable responses continue with selected lymphocyte infusions such as CD8 þ cells, selected NK cell infusions or vaccine strategies currently underway.
